ClariTrial — AI Clinical Trial Intelligence

Explore/PROTAC molecular glue protein degradation

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

5 results for “PROTAC molecular glue protein degradation” · Recruiting

↩No exact matches for “PROTAC molecular glue protein degradation”. Showing results for “PROTAC” instead.

Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer

DT2216Paclitaxel

Elizabeth Stover, MD, PhD30 participants3 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Solid TumorAdvanced Solid TumorSolid Tumor, Adult

NKT3964

NiKang Therapeutics, Inc.150 participants19 sites · United StatesCompletes Jan 2029

CT.gov Full analysis →

Recruiting

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Phase 1Advanced Prostate Cancer

HS-20093HRS-5041

Hansoh BioMedical R&D Company63 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

CT.gov Full analysis →

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 1Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants41 sites · United States, Australia, ChinaCompletes Feb 2028

CT.gov Full analysis →

1–5 of 5

Explore/PROTAC molecular glue protein degradation

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

5 results for “PROTAC molecular glue protein degradation” · Recruiting

↩No exact matches for “PROTAC molecular glue protein degradation”. Showing results for “PROTAC” instead.

Recruiting

DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer

Phase 1Ovarian CancerOvarian CarcinomaRecurrent Ovary Cancer

DT2216Paclitaxel

Elizabeth Stover, MD, PhD30 participants3 sites · United StatesCompletes Dec 2026

CT.gov Full analysis →

Recruiting

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Phase 1Solid TumorAdvanced Solid TumorSolid Tumor, Adult

NKT3964

NiKang Therapeutics, Inc.150 participants19 sites · United StatesCompletes Jan 2029

CT.gov Full analysis →

Recruiting

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Phase 1Advanced Prostate Cancer

HS-20093HRS-5041

Hansoh BioMedical R&D Company63 participants1 site · ChinaCompletes Dec 2027

CT.gov Full analysis →

Recruiting

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

Phase 1Phase 2Childhood Fibrolamellar CarcinomaRecurrent Childhood Fibrolamellar CarcinomaRecurrent Childhood Malignant Solid Neoplasm

Bcl-XL Proteolysis Targeting Chimera DT2216Biospecimen CollectionIrinotecan

Children's Oncology Group81 participants20 sites · United StatesCompletes Dec 2031

CT.gov Full analysis →

Recruiting

Study of PF-07248144 in Advanced or Metastatic Solid Tumors

Phase 1Locally Advanced or Metastatic ER+ HER2- Breast CancerLocally Advanced or Metastatic Castration-resistant Prostate CancerLocally Advanced or Metastatic Non-small Cell Lung Cancer

PF-07248144FulvestrantLetrozole+3 more

Pfizer320 participants41 sites · United States, Australia, ChinaCompletes Feb 2028

CT.gov Full analysis →

1–5 of 5